Severe acute respiratory syndrome-related coronavirus

ViralClear Partners with Catalent on Potential Treatment for COVID-19

Retrieved on: 
Monday, June 22, 2020
Health, Zoonoses, Catalent, Medicine, Severe acute respiratory syndrome-related coronavirus, Severe acute respiratory syndrome, Virus, Pharmaceutical industry in China, Medication

ViralClear is undertaking research to investigate the potential of Merimepodib to fight the SARS-CoV-2 virus, either as a standalone treatment, or in combination with other anti-viral agents or immune modulators.

Key Points: 
  • ViralClear is undertaking research to investigate the potential of Merimepodib to fight the SARS-CoV-2 virus, either as a standalone treatment, or in combination with other anti-viral agents or immune modulators.
  • He continued, ViralClear is committed to using US-based contract development and manufacturing organizations for the development and commercialization of merimepodib.
  • Catalent will work on the program at its St. Petersburg, Florida, facility, manufacturing oral solution for clinical studies, as well as undertaking feasibility studies on other liquid-filled oral formulations.
  • BioSig Technologies, Inc.s (Nasdaq: BSGM) subsidiary, ViralClear Pharmaceuticals, Inc., is seeking to develop a novel pharmaceutical called merimepodib to treat patients with COVID-19.

Xenex Announces StrikeForce Disinfection Service; LightStrike Robot Destroys COVID-19 Virus in 2 Minutes

Retrieved on: 
Monday, June 22, 2020
Medical Supplies, Health, Technology, Infectious diseases, Hospitals, Other Technology, Viruses, Coronaviridae, Zoonoses, Hygiene, Ultraviolet radiation, Animal virology, Coronavirus, Severe acute respiratory syndrome-related coronavirus, Severe acute respiratory syndrome, Ultraviolet germicidal irradiation, Disinfectant, Ultraviolet

As cities across Texas report a spike in the number of coronavirus cases, businesses and organizations are looking for strategies to combat the virus within their facilities.

Key Points: 
  • As cities across Texas report a spike in the number of coronavirus cases, businesses and organizations are looking for strategies to combat the virus within their facilities.
  • Xenex Disinfection Services , the world leader in UV disinfection for healthcare facilities, today announced the launch of StrikeForce, an innovative disinfection service.
  • The LightStrike disinfection robot is proven to destroy Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, in two minutes.
  • With broad spectrum germicidal light, Xenex LightStrike robots quickly deactivate viruses, bacteria and spores where they are most vulnerable without damaging materials or equipment.

National Jewish Health Launches Additional Coronavirus Test

Retrieved on: 
Monday, June 22, 2020
Zoonoses, Severe acute respiratory syndrome-related coronavirus, Medicine, Severe acute respiratory syndrome, Animal diseases, Health, In Saudi Arabia, Middle East respiratory syndrome, Medical tests

DENVER, June 22, 2020 /PRNewswire/ --National Jewish Health has added a new molecular test and platform to detect the SARS-CoV-2 virus.

Key Points: 
  • DENVER, June 22, 2020 /PRNewswire/ --National Jewish Health has added a new molecular test and platform to detect the SARS-CoV-2 virus.
  • executive vice president clinical affairs, at National Jewish Health "This new SARS-CoV-2 test adds another reliable testing mechanism as we expand testing even more broadly for our patients and the community."
  • National Jewish Health offers both molecular testing to diagnose COVID-19 and antibody testing to identify people who have had the disease.
  • National Jewish Health collaborated with Agena Bioscience to develop the assay, which will run on the Agena Bioscience MassARRAY System.

The Impact of COVID-19 on Early Clinical Development - What the New Landscape Will Look Like, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, June 22, 2020
Zoonoses, Severe acute respiratory syndrome-related coronavirus, Infection, Severe acute respiratory syndrome, Health, Medicine, Epidemiology

What is known about COVID-19, the unexpected variation in its clinical presentation, in adults and in children, and the short- and long-term effects?

Key Points: 
  • What is known about COVID-19, the unexpected variation in its clinical presentation, in adults and in children, and the short- and long-term effects?
  • How can active infection with SARS-CoV-2 be reliably measured and how can previous infection be proved by measuring immune response?
  • For more information or to register for this event, visit The Impact of COVID-19 on Early Clinical Development What the New Landscape Will Look Like .
  • Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

Altoros Launches a Mass Temperature Screener to Minimize the Spread of COVID-19

Retrieved on: 
Monday, June 22, 2020
Screener, Severe acute respiratory syndrome-related coronavirus, Thermoregulation, Branches of biology, Organisms, Academic disciplines

Powered by artificial intelligence (AI), Temperature Screener identifies individuals with high body temperaturea major symptom of the SARS-CoV-2 virus.

Key Points: 
  • Powered by artificial intelligence (AI), Temperature Screener identifies individuals with high body temperaturea major symptom of the SARS-CoV-2 virus.
  • "With Temperature Screener, we can quickly assess a large number of people to identify if someone has an elevated body temperature.
  • Temperature Screener supports recurrent temperature monitoringi.e., diagnosing a potentially infected individual at specified time intervals.
  • Temperature Screener is a fully automatic enterprise-grade product enabling organizations to set up temperature scanning checkpoints.

IncellDx Files Patent for CCL5/RANTES Utility as a Diagnostic, Prognostic, and Therapeutic Biomarker in COVID-19 and Other Cytokine Storm Conditions

Retrieved on: 
Thursday, June 18, 2020
Health, Infectious diseases, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Viruses, Medical specialties, Medicine, Cytokines, Coronaviridae, Immunology, Animal virology, CCL5, Zoonoses, Cytokine, Coronavirus, Severe acute respiratory syndrome-related coronavirus

IncellDx announces the patent filing with the USPTO and the Pre-EUA with the FDA for CCL5/RANTES Utility as a Diagnostic, Prognostic, and Therapeutic Biomarker in COVID-19.

Key Points: 
  • IncellDx announces the patent filing with the USPTO and the Pre-EUA with the FDA for CCL5/RANTES Utility as a Diagnostic, Prognostic, and Therapeutic Biomarker in COVID-19.
  • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of a novel coronavirus disease 2019 (COVID-19), is now a global pandemic.
  • Other Cytokines included in the COVID-19 Cytokine Panel can be used to monitor other COVID-19 therapeutic approaches targeting other cytokines involved in the cytokine storm.
  • Company files Pre-EUA with FDA for CCR5 receptor occupancy and a COVID cytokine panel including IL-6, IL-8,TNF-a, GM-CSF, and CCL5/RANTES.

Avacta provides update on Affimer therapy for COVID-19 infection

Retrieved on: 
Thursday, June 18, 2020
Health, Infectious diseases, Research, Pharmaceutical, Science, Biotechnology, Affimer, Zoonoses, Medicine, Branches of biology, Health, Severe acute respiratory syndrome-related coronavirus, Severe acute respiratory syndrome, Virus, Immunology, In Saudi Arabia, Middle East respiratory syndrome

Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and reagents, is pleased to announce that collaborative work with the Centre for Virus Research at the University of Glasgow has shown that Affimer reagents which bind to the SARS-COV-2 virus spike protein prevent infection of human cells by a SARS-COV-2 model virus and therefore provide a potential therapy for COVID-19 infection.

Key Points: 
  • Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and reagents, is pleased to announce that collaborative work with the Centre for Virus Research at the University of Glasgow has shown that Affimer reagents which bind to the SARS-COV-2 virus spike protein prevent infection of human cells by a SARS-COV-2 model virus and therefore provide a potential therapy for COVID-19 infection.
  • Avacta has now successfully completed the initial phase of a collaboration with Professor David Bhella at the University of Glasgow showing that these neutralising Affimer reagents prevent a SARS-COV-2 model virus from entering human cells and therefore provide a potential therapy for COVID-19.
  • Work is continuing with Professor Bhella to further study the way in which the Affimer reagents prevent infection and Avacta is using this growing body of data actively to secure a large pharmaceutical partner to develop these potential therapeutic candidates rapidly.
  • Given the excellent performance of these novel reagents in the assays, and the other benefits of Affimer reagents, there should be considerable interest from potential partners in developing them as a therapy for COVID-19.

Ascend Collaborates on Research to Estimate the Exposure to SARS-CoV-2 Among the U.S. Dialysis Population

Retrieved on: 
Wednesday, June 17, 2020
Medicine, Natural sciences, Chemistry, Membrane technology, Detoxification, Dialysis, Assay, Severe acute respiratory syndrome-related coronavirus, Severe acute respiratory syndrome, Immunoassay

Ascend will use the FDA, EUA approved SARS-CoV-2 Total Antibody assay from Siemens Healthineers, utilizing their high throughput Atellica immunoassay instrument.

Key Points: 
  • Ascend will use the FDA, EUA approved SARS-CoV-2 Total Antibody assay from Siemens Healthineers, utilizing their high throughput Atellica immunoassay instrument.
  • "Ascend has been dedicated to the dialysis community,"said Paul Beyer, CEO, Ascend.
  • The research aims to estimate the exposure to the virus that causes COVID-19 in the U.S. dialysis population and understand the rates of protective immunity over time.
  • Founded in 1984, Ascend Clinical is the leader in end-stage renal disease (ESRD) laboratory testing services for independent and hospital-based dialysis clinics throughoutthe United States.

aTyr Pharma Highlights New Literature Implicating Neuropilin Pathway In SARS-CoV-2 Infection

Retrieved on: 
Wednesday, June 17, 2020
Severe acute respiratory syndrome-related coronavirus, Neuropilin, Severe acute respiratory syndrome, Branches of biology, Medicine, Epidemiology

A recent article published in the New England Journal of Medicine (Ackermann M., Verleden S.E., Kuehnel M., et al.)

Key Points: 
  • A recent article published in the New England Journal of Medicine (Ackermann M., Verleden S.E., Kuehnel M., et al.)
  • These studies also demonstrate that preventing this binding interaction results in decreased cell infection.
  • The authors of these studies indicate that Neuropilins may be a target for therapeutic approaches to reduce SARS-CoV-2 viral infection.
  • aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways.

Chembio Investors: Company Investigated by the Portnoy Law Firm

Retrieved on: 
Wednesday, June 17, 2020
Glycoproteins, Branches of biology, Antibodies, Biology, Immunology, Severe acute respiratory syndrome-related coronavirus, Immunoglobulin G, Immunoglobulin M, Portnoy

LOS ANGELES, June 17, 2020 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Chembio Diagnostic System, Inc. (NASDAQ: CEMI ) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.

Key Points: 
  • LOS ANGELES, June 17, 2020 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Chembio Diagnostic System, Inc. (NASDAQ: CEMI ) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors options for pursuing claims to recover their losses.
  • The Portnoy Law Firm investigation focuses on whether the Company misled investors regarding its FDA authorization for the Chembio Diagnostic System DPP COVID-19 IgM/IgG System, a SARS-CoV-2 antibody test (the DPP Test).
  • The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing.